产品
编 号：F424496
分子式：C13H9ClN2O6S
分子量：356.74
分子式：C13H9ClN2O6S
分子量：356.74
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
询价
询价
250mg
询价
询价
结构图
CAS No: 68003-38-3
产品详情
生物活性：
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity.
体内研究：
CTPI-2 is a unique regulator of glycolysis that limits the metabolic plasticity of cancer stem cells (CSCs). CTPI-2 (26?mg/kg; i.p.) inhibits tumor growth in in vivo models of non-small cell lung cancer (NSCLC).?CTPI-2 (50 mg/kg; i.p.; alternate days for 12 weeks) completely averts weight gain in the prevention study and leads to significant weight loss in the reversion study.?CTPI-2 prevents steatohepatitis and normalizes glucose tolerance. CTPI-2 lowers the levels of circulating IL-6 while increasing anti-inflammatory IL-4 and IL-10 and also reduced the monocyte chemoattractant protein-1 and monokine-induced by interferon-γ that attract neutrophils and monocytes. CTPI-2 regulates the citrate pool, the lipogenic and the gluconeogenic pathways.Animal Model:C57BL/6J mice (HFD-fed mice)
Dosage:50 mg/kg
Administration:Alternate days via the intraperitoneal route for 12 weeks
Result:Completely averted weight gain in the prevention study and led to significant weight loss in the reversion study.
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity.
体内研究：
CTPI-2 is a unique regulator of glycolysis that limits the metabolic plasticity of cancer stem cells (CSCs). CTPI-2 (26?mg/kg; i.p.) inhibits tumor growth in in vivo models of non-small cell lung cancer (NSCLC).?CTPI-2 (50 mg/kg; i.p.; alternate days for 12 weeks) completely averts weight gain in the prevention study and leads to significant weight loss in the reversion study.?CTPI-2 prevents steatohepatitis and normalizes glucose tolerance. CTPI-2 lowers the levels of circulating IL-6 while increasing anti-inflammatory IL-4 and IL-10 and also reduced the monocyte chemoattractant protein-1 and monokine-induced by interferon-γ that attract neutrophils and monocytes. CTPI-2 regulates the citrate pool, the lipogenic and the gluconeogenic pathways.Animal Model:C57BL/6J mice (HFD-fed mice)
Dosage:50 mg/kg
Administration:Alternate days via the intraperitoneal route for 12 weeks
Result:Completely averted weight gain in the prevention study and led to significant weight loss in the reversion study.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备